Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
6,624.70
(
-1.36%
)
US TECH 100
23,776.40
(
-1.48%
)
Dow Jones
46,225.15
(
-1.63%
)
Brent Oil
107.10
(
6.41%
)
Bitcoin
71,324.92
(
-3.54%
)
News Focus
News Focus
Post# of 257257
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 842
Posts 122795
Boards Moderated 10
Alias Born 09/05/2002

DewDiligence

Member Level

Re: DewDiligence post# 62186

Tuesday, 11/04/2008 3:31:22 PM

Tuesday, November 04, 2008 3:31:22 PM

Post# of 257257
Re: IDIX / IDX899 partnership discussions

CEO JP Sommadossi said on today’s Oppenheimer webcast that IDIX began partnership discussions in June after IDIX reported data from the 200mg cohort (#msg-29959114). In September, when IDIX reported data from the 100mg cohort (#msg-31925486), additional prospective partners joined the discussions.

Why so much emphasis on the precise dose? Because the prospective partners want to coformulate IDX899 with their own HIV drug(s).

IDIX continues to guide for a partnership announcement before year-end.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Trade Smarter with Thousands

Leverage decades of market experience shared openly.

Join Now